UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Updates on targeting human epidermal growth factor receptor 2-positive breast cancer: what's to know in 2021

Current opinion in obstetrics & gynecology, 2022-02, Vol.34 (1), p.41-45

McAndrew, Nicholas P

2022

Volltextzugriff (PDF)

Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor

Breast cancer research : BCR, 2023-07, Vol.25 (1), p.81-81, Article 81

2023

Volltextzugriff (PDF)

Early treatment-related neutropenia predicts response to palbociclib

British journal of cancer, 2020-09, Vol.123 (6), p.912-918

2020

Volltextzugriff (PDF)

A careful reassessment of anthracycline use in curable breast cancer

NPJ breast cancer, 2021-10, Vol.7 (1), p.134-134, Article 134

2021

Volltextzugriff (PDF)

Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysis

Therapeutic advances in medical oncology, 2022, Vol.14, p.17588359221085556-17588359221085556

2022

Volltextzugriff (PDF)

Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer

Discover. Oncology, 2024-09, Vol.15 (1), p.467-9, Article 467

2024

Volltextzugriff (PDF)

Effects of systemic inflammation on relapse in early breast cancer

NPJ breast cancer, 2021-01, Vol.7 (1), p.7-7, Article 7

2021

Volltextzugriff (PDF)

Management of ER positive metastatic breast cancer

Seminars in oncology, 2020-10, Vol.47 (5), p.270-277

2020

Volltextzugriff (PDF)

Clinical Review on the Management of Hormone Receptor-Positive Metastatic Breast Cancer

JCO oncology practice, 2022-05, Vol.18 (5), p.319-327

2022

Volltextzugriff (PDF)

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer

NPJ breast cancer, 2022-11, Vol.8 (1), p.122-9, Article 122

2022

Volltextzugriff (PDF)

Systemic Therapy for Early- and Late-Stage, Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer

Hematology/oncology clinics of North America, 2023-02, Vol.37 (1), p.103-115

2023

Volltextzugriff (PDF)

Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer

Clinical cancer research, 2019-04, Vol.25 (7), p.2072-2079

2019

Volltextzugriff (PDF)

Pathologic Complete Response as a Surrogate Endpoint in Breast Cancer

Oncology & Haematology, 2021, Vol.17 (1), p.12

2021

Volltextzugriff (PDF)

Rectal Cancer Survival for Residual Carcinoma In Situ Versus Pathologic Complete Response After Neoadjuvant Therapy

Diseases of the colon & rectum, 2024-07, Vol.67 (7), p.920

2024

Volltextzugriff (PDF)

Rectal Cancer Survival for Residual Carcinoma In Situ Vs. Pathologic Complete Response After Neoadjuvant Therapy

Diseases of the colon & rectum, 2024-03

2024

Volltextzugriff (PDF)

Abstract LB052: Cell cycle synchronization: Biomarker analysis in a phase I trial of alternating ribociclib and paclitaxel in advanced breast cancer

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.LB052-LB052

2021

Volltextzugriff (PDF)

Abstract P4-01-23: Updated data from the phase 1 trial of DZD1516, a BBB-penetrant selective HER2 inhibitor, in patients with HER2 positive metastatic breast cancer

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P4-P4-01-23

2023

Volltextzugriff (PDF)

Abstract P3-03-13: Long-term heart failure risk of trastuzumab with or without anthracyclines in early stage breast cancer: A SEER-Medicare Database Analysis

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P3-P3-03-13

2023

Volltextzugriff (PDF)

Abstract OT1-12-05: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT1-12-05-OT1-12-05

2022

Volltextzugriff (PDF)

Tumors at the aortoiliac/inferior vena cava bifurcation : Preoperative, anesthetic, and intraoperative considerations

The American surgeon, 2007-05, Vol.73 (5), p.440-446

2007

Volltextzugriff (PDF)

Abstract GS2-03: GS2-03 TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.GS2-03-GS2-03

2023

Volltextzugriff (PDF)

Why CDK 4/6 Inhibitors are Practice Changing in Advanced Breast Cancer

Oncology & Hematology Review (US), 2020, Vol.16 (1), p.23

2020

Volltextzugriff (PDF)

Impact of large periprocedural myocardial infarction on mortality after percutaneous coronary intervention and coronary artery bypass grafting for left main disease: an analysis from the EXCEL trial

European heart journal, 2019-06, Vol.40 (24), p.1930-1941

2019

Volltextzugriff (PDF)

Acute myocardial infarction activates distinct inflammation and proliferation pathways in circulating monocytes, prior to recruitment, and identified through conserved transcriptional responses in mice and humans

European heart journal, 2015-08, Vol.36 (29), p.1923-1934

2015

Volltextzugriff (PDF)

Autoantibodies targeting TLR and SMAD pathways define new subgroups in systemic lupus erythematosus

Journal of autoimmunity, 2018-07, Vol.91, p.1-12

2018

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(39)
Tagungsberichte
(2)

Sprache

Englisch
(41)

Erscheinungsjahr

n.n

Thema

Science & Technology
(29)
Life Sciences & Biomedicine
(23)
Humans
(16)
Female
(15)
Oncology
(12)
Breast Cancer
(11)
Male
(11)
Middle Aged
(9)
Patients
(6)
Adult
(5)
Aged
(5)
Cancer Research
(5)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Biomedical And Life Sciences
(4)
Biomedicine
(4)
Breast Neoplasms - Drug Therapy
(4)
Cancer Therapies
(4)
Cardiac & Cardiovascular Systems
(4)
Cardiovascular System & Cardiology
(4)
Percutaneous Coronary Intervention
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Updates on targeting human epidermal growth factor receptor 2-positive breast cancer: what's to know in 2021

Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor

Early treatment-related neutropenia predicts response to palbociclib

A careful reassessment of anthracycline use in curable breast cancer

Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysis

Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer

Effects of systemic inflammation on relapse in early breast cancer

Management of ER positive metastatic breast cancer

Clinical Review on the Management of Hormone Receptor-Positive Metastatic Breast Cancer

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer

Systemic Therapy for Early- and Late-Stage, Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer

Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer

Pathologic Complete Response as a Surrogate Endpoint in Breast Cancer

Rectal Cancer Survival for Residual Carcinoma In Situ Versus Pathologic Complete Response After Neoadjuvant Therapy

Rectal Cancer Survival for Residual Carcinoma In Situ Vs. Pathologic Complete Response After Neoadjuvant Therapy

Abstract LB052: Cell cycle synchronization: Biomarker analysis in a phase I trial of alternating ribociclib and paclitaxel in advanced breast cancer

Abstract P4-01-23: Updated data from the phase 1 trial of DZD1516, a BBB-penetrant selective HER2 inhibitor, in patients with HER2 positive metastatic breast cancer

Abstract P3-03-13: Long-term heart failure risk of trastuzumab with or without anthracyclines in early stage breast cancer: A SEER-Medicare Database Analysis

Abstract OT1-12-05: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer

Tumors at the aortoiliac/inferior vena cava bifurcation : Preoperative, anesthetic, and intraoperative considerations

Abstract GS2-03: GS2-03 TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer

Why CDK 4/6 Inhibitors are Practice Changing in Advanced Breast Cancer

Impact of large periprocedural myocardial infarction on mortality after percutaneous coronary intervention and coronary artery bypass grafting for left main disease: an analysis from the EXCEL trial

Acute myocardial infarction activates distinct inflammation and proliferation pathways in circulating monocytes, prior to recruitment, and identified through conserved transcriptional responses in mice and humans

Autoantibodies targeting TLR and SMAD pathways define new subgroups in systemic lupus erythematosus

Suchergebnisse filtern